IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene KLK3 Ensembl ENSG00000142515 Chromosome 19 Start 56049983 End 56055832
Description Prostate-specific antigen Precursor (PSA)(EC 3.4.21.77)(Kallikrein-3)(Semenogelase)(Gamma-seminoprotein)(Seminin)(P-30 antigen) [Source:UniProtKB/Swiss-Prot;Acc:P07288]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 6364
     Entrez Gene : 354
     UCSC : uc010ycj.1
     GeneCards : 6364
     RefSeq : NM_001030047
     CCDS : CCDS12807.1
     Uniprot : P07288
     Interpro : P07288
     OMIM : 176820
     GeneTests : KLK3
     CGAP : KLK3
     PMID : 2456523

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1513_at  0.07  3.23e-1  4.28e-1  -0.04  6.62e-1  7.46e-1
 HG_U95  1514_g_at  -0.40  6.97e-3  1.71e-2  -0.09  7.25e-1  7.98e-1
 HG_U95  1661_i_at  0.04  7.95e-1  8.54e-1  0.01  9.46e-1  9.64e-1
 HG_U95  1804_at  0.63  3.39e-10  4.63e-9  0.56  1.80e-4  6.78e-4
 HG_U95  1805_g_at  -0.00  9.93e-1  9.95e-1  0.06  8.03e-1  8.59e-1
 HG_U95  40794_at  0.05  6.85e-1  7.66e-1  -0.05  7.42e-1  8.12e-1
 HG_U133A  204582_s_at  -0.12  2.48e-1  2.98e-1  3.76  1.94e-93  1.10e-92
 HG_U133A  204583_x_at  -0.44  2.41e-4  4.76e-4  3.37  1.29e-82  5.57e-82
 HG_U133_Plus2  204582_s_at  0.35  2.22e-2  4.14e-2  0.17  2.97e-1  3.56e-1
 HG_U133_Plus2  204583_x_at  0.25  1.05e-1  1.59e-1  0.50  4.64e-3  8.01e-3
 HG_U133_Plus2  231629_x_at  0.48  7.65e-6  2.98e-5  0.99  2.10e-13  1.38e-12
 Stanford  676  0.07  9.02e-1  9.48e-1  0.34  5.32e-1  7.40e-1
 Stanford  733  0.34  3.60e-1  5.60e-1  0.81  1.25e-1  3.16e-1
 Stanford  1489  0.34  3.60e-1  5.60e-1  0.81  1.25e-1  3.16e-1
 Stanford  2245  0.34  3.60e-1  5.60e-1  0.81  1.25e-1  3.16e-1
 Stanford  3001  0.34  3.60e-1  5.60e-1  0.81  1.25e-1  3.16e-1
 Stanford  8292  -0.22  6.84e-1  8.16e-1  0.26  7.35e-1  8.71e-1
 Stanford  9753  -0.56  6.32e-2  1.82e-1  -0.62  3.01e-1  5.41e-1
 Stanford  15045  -0.21  5.14e-1  6.93e-1  0.06  8.85e-1  9.49e-1
 Stanford  15801  -0.71  1.43e-2  8.10e-2  -0.59  1.92e-1  4.14e-1
 Stanford  15824  0.25  5.77e-1  7.40e-1  -0.10  8.63e-1  9.39e-1
 Stanford  22623  -0.02  9.29e-1  9.63e-1  -0.04  9.11e-1  9.61e-1
 Agilent_HS_21.6K  17429  0.26  1.32e-2  5.61e-2  0.25  8.69e-3  3.20e-2

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  204582_s_at  -0.22  4.43e-1  9.14e-1  0.32  5.17e-2  1.00e+0
 HG_U133A  204583_x_at  0.32  2.66e-1  8.61e-1  0.07  7.35e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1513_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1514_g_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1661_i_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1804_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1805_g_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 40794_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204582_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204583_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204582_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204583_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 231629_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 676    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 733    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 1489    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 2245    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 3001    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 8292    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 9753    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 15045    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 15801    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 15824    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 22623    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 17429    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
klk3 prostatic adenocarcinoma KLK3 or prostate specific antigen (PSA) is a serine protease, which is an established tumour marker of prostatic adenocarcinoma. 10188912 Human
prostate specific antigen metastatic adenocarcinoma Newer immunohistochemical staining techniques for prostate specific antigen and prostatic acid phosphatase can assist in localization of the metastatic adenocarcinoma to a prostatic origin. 6195357 Human
prostate specific antigen granulomas In the prostate, no reaction by antibodies against prostate specific antigen was observed in the granulomas. 2449682 Human
prostate specific antigen primary tumor Quantification of prostatic acid phosphatase and prostate specific antigen in the primary tumor cells probably will not offer a predictive value for the eventual behavior of the tumors. 2448499 Human
prostate specific antigen adenocarcinoid tumor [Prostatic carcinoid and neuroendocrine tumors--a case report] This paper reports a rare primary prostatic adenocarcinoid tumor confirmed by electron microscopy as well as immunohistochemical method including prostate specific antigen and prostatic acid p 3416705 Human
prostate specific antigen metastatic prostatic adenocarcinoma The prostate specific antigen was exclusively positive for metastatic prostatic adenocarcinoma with a low frequency and prostate acid phosphatase had many false positive results. 2462648 Human
prostate specific antigen poorly differentiated adenocarcinoma One case exhibited positive staining for prostate specific antigen (PSA) and was associated with an underlying, invasive poorly differentiated adenocarcinoma of unknown primary. 2536589 Human
prostate specific antigen metastastic disease Increasing prostate specific antigen values after radiotherapy were correlated with progression to metastastic disease and residual cancer on prostate biopsy. 2468796 Human
prostate specific antigen stage a1 prostate cancer Among patients with stage A1 prostate cancer who were followed expectantly none had an elevated prostate specific antigen value or metastatic disease during a followup of 15 to 120 months. 2477559 Human
prostate specific antigen transitional cell carcinoma The transperineal biopsy of the prostate revealed the transitional cell carcinoma with negative staining of Alcian-Blue, PAS and PSA (prostate specific antigen). 2678986 Human
prostate specific antigen primary tumor Immunohistochemical stains for prostate specific acid phosphatase and prostate specific antigen were positive in the primary tumor and regional metastases. 2294240 Human
prostate specific antigen primary tumor Prostate specific antigen levels were proportional to the estimated volume of the primary tumor (p less than 0.0065). 1695690 Human
prostate specific antigen adenocarcinoma The adenocarcinoma of the prostate stained with antibodies to panepithelial antigen (lu-5), prostatic acid phosphatase, prostate specific antigen and CEA, whereas the adenocarcinoma of the seminal vesicles reacted only to lu-5 and CEA. 2201434 Human
prostate specific antigen localized carcinoma A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. 1698754 Human
prostate specific antigen stage a prostate cancer The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. 1700143 Human
prostate specific antigen carcinoid We report a case of carcinoid, diagnosed histochemically and biochemically, which was associated with grossly elevated serum prostatic acid phosphatase and normal serum prostate specific antigen. 2235095 Human
prostate specific antigen stage c prostate cancer Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade. 1706439 Human
prostate specific antigen stage c prostate cancer The preoperatively drawn sera from 84 previously untreated patients who had clinical stage C prostate cancer and underwent staging pelvic lymph node dissections were sent for monoclonal Hybritech analysis to assess the usefulness of prostate specific anti 1706439 Human
prostate specific antigen undifferentiated prostatic carcinomas Thirteen undifferentiated bladder tumours and 10 undifferentiated prostatic carcinomas were incubated with E48 and prostate specific antigen. 1374431 Human
prostate specific antigen bladder tumours Thirteen undifferentiated bladder tumours and 10 undifferentiated prostatic carcinomas were incubated with E48 and prostate specific antigen. 1374431 Human
prostate specific antigen renal-cell carcinoma False positive prostate specific antigen values in the sera of women with renal cell carcinoma. 1377289 Human
prostate specific antigen renal-cell carcinoma The assessment of serum prostate specific antigen (PSA) with a polyclonal radioimmunoassay in 22 women with renal cell carcinoma resulted in measurable values in 6 patients, with the values ranging from 0.5 to 27.0 ng./ml. 1377289 Human
prostate specific antigen localized carcinoma Prostate specific antigen levels during and after external beam radiotherapy for localized carcinoma of the prostate: predictor of therapeutic efficacy. 1379747 Human
prostate specific antigen mucinous adenocarcinoma of the prostate A 56-year-old man underwent subcapsular prostatectomy under the diagnosis of benign prostatic hyperplasia in 1968, and was found to have mucinous adenocarcinoma of the prostate, which proved to be prostatic acid phosphatase (PAP) and prostate specific ant 1326881 Human
prostate specific antigen recurrent prostate cancer Recurrent prostate cancer despite undetectable prostate specific antigen. 1279216 Human
prostate specific antigen recurrent tumor We investigated whether urinary prostate specific antigen (PSA) might be a useful marker to detect locally recurrent tumor after radical prostatectomy. 7681118 Human
prostate specific antigen recurrent cancer The combination of prostate specific antigen (PSA) and transrectal ultrasonography was used to detect recurrent cancer in the prostatic fossa after radical prostatectomy. 7683341 Human
prostate specific antigen recurrent colon cancers Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly. 7510220 Human
prostate specific antigen renal-cell carcinoma Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma. 7508527 Human
prostate specific antigen stage c prostate cancer Radiation therapy may be beneficial after radical prostatectomy in some patients with pathological stage C prostate cancer and in those with detectable postoperative prostate specific antigen (PSA) levels. 7514691 Human
prostate specific antigen prostate for benign hyperplasia (bph) The relationship between the serum values of prostate specific antigen (PSA) and the extent of histological prostatitis was investigated in 42 patients undergoing transurethral resection of the prostate for benign hyperplasia (BPH) without clinical eviden 7518599 Human
prostate specific antigen metastatic prostate cancer Pretreatment assessment of men diagnosed with metastatic prostate cancer should include prognostic factors (tumor volume, histologic grade, DNA ploidy, and prostate specific antigen), health status (comorbidity and performance status), quality of life fac 8087788 Human
prostate specific antigen t2 prostate cancer Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. 7523725 Human
prostate specific antigen t2 prostate cancer Assessment of outcome following radical treatment for stages T1 to T2 prostate cancer has become more sensitive and rapid with the use of serum prostate specific antigen (PSA) in routine followup. 7523726 Human
prostate specific antigen recurrent cancer We reviewed our experience with salvage radical prostatectomy for locally recurrent cancer in 40 patients to assess the current complication rate and the results using prostate specific antigen (PSA) as an indicator of treatment outcome and to identify be 7526002 Human
prostate specific antigen recurrent tumor Progressive elevation of the prostate specific antigen (PSA) level after radical prostatectomy for adenocarcinoma is generally considered as irrefutable evidence of recurrent tumor. 7531783 Human
prostate specific antigen hamartoma The malignant glands within the hamartoma showed strong reactivity for prostate specific antigen, excluding the possibility of malignant change within the hamartoma. 7694949 Human
prostate specific antigen progressive metastatic prostate cancer We report a dramatic decrease in prostate specific antigen in response to the discontinuation of megestrol acetate in a patient with progressive metastatic prostate cancer. 7538601 Human
prostate specific antigen malignant glioma One patient with refractory malignant glioma had a partial response, and one with hormone-independent prostate cancer achieved a 50% decline in prostate specific antigen level, which was maintained for 1 month. 7773944 Human
prostate specific antigen metastatic cancer PURPOSE: We assess the impact of deferred flutamide treatment on the serum prostate specific antigen (PSA) level in patients with localized or metastatic cancer. 7541862 Human
prostate specific antigen clear-cell adenocarcinoma The tumor cells were stained positively with antibodies to prostate specific antigen (PSA) and prostatic acid phosphatase (PAP), suggesting that the clear cell adenocarcinoma arises from the female paraurethral duct, rather than embryonic remnant. 7645457 Human
prostate specific antigen urological cancer PSA (prostate specific antigen) and PSMA (prostate specific membrane antigen) serum levels were determined in over 235 prostate cancer patients from 8 different United States clinical urological cancer centers. 7544569 Human
prostate specific antigen recurrent carcinoma PURPOSE: Serum prostate specific antigen (PSA) has been reported to be a sensitive indicator of recurrent carcinoma after radical prostatectomy but it is not absolute. 7500474 Human
prostate specific antigen primary tumour There was no statistically significant correlation between this finding and established risk factors, such as the volume and histological grade of the primary tumour or the concentration of prostate specific antigen and prostatic acid phosphatase in serum 7488413 Human
prostate specific antigen prostatic intraepithelial neoplasia Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? 8640677 Human
prostate specific antigen prostatic intraepithelial neoplasia (pin) BACKGROUND. Prostatic intraepithelial neoplasia (PIN) is considered to be a precursor of prostate carcinoma in which serum levels of prostate specific antigen (PSA) have been correlated with PIN grades. 8640677 Human
prostate specific antigen metastatic prostate carcinoma Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. 8630883 Human
prostate specific antigen adenocarcinoma Immunohistochemical staining revealed cytoplasmic reactivity for prostate specific antigen or keratin in 16 of 16 cases in the adenocarcinoma component. 8625205 Human
prostate specific antigen breast cyst Prostate specific antigen--a new constituent of breast cyst fluid. 8739078 Human
prostate specific antigen breast cyst We demonstrate for the first time that prostate specific antigen (PSA) is a component of breast cyst fluid. 8739078 Human
prostate specific antigen solid tumor Response was assessed with a combination of standard solid tumor response criteria and the serum prostate specific antigen (PSA) for patients with bidimensionally measurable disease, and by serial measurements of the PSA in patients with bone only (evalua 8729952 Human
prostate specific antigen advanced cancer RESULTS: Black men had a higher prevalence of elevated prostate specific antigen (13.1 versus 8.9%) and cancer (5.1 versus 3.2%) than white men, and a higher prevalence of clinically but not pathologically advanced cancer. 8808873 Human
prostate specific antigen prostatic adenoma The AUA symptom scores improved on average by 6.3 points; prostatic adenoma volume reduced from baseline by 17%, and the serum prostate specific antigen (PSA) level decreased by 35%. 8851481 Human
prostate specific antigen metastatic carcinoma The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. 8881955 Human
prostate specific antigen adenoma Higher prostate specific antigen (PSA) levels in Group II may be explained by the greater size of the adenoma. 9000839 Human
prostate specific antigen leukemia Other cancers, primarily leukemia and lymphoma, can involve the prostate and lead to an abnormal digital examination or elevated serum prostate specific antigen (PSA). 9237794 Human
prostate specific antigen lymphoma Other cancers, primarily leukemia and lymphoma, can involve the prostate and lead to an abnormal digital examination or elevated serum prostate specific antigen (PSA). 9237794 Human
prostate specific antigen recurrent prostate cancer PURPOSE: Commonly available prostate specific antigen (PSA) assays have detection limits of greater than 0.05 ng/ml., limiting their ability to identify residual or recurrent prostate cancer after radical prostatectomy or to provide prognostic information 9120931 Human
prostate specific antigen metastatic carcinoma PURPOSE: Prostate specific antigen (PSA), prostatic acid phosphatase and alkaline phosphatase were analyzed in 2 large prospective multicenter and multinational trials to assess their correlation with time to progression and overall survival after hormona 9120932 Human
prostate specific antigen metastatic melanomas Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas. 9216712 Human
prostate specific antigen polyps The polyps contained acini and papillae lined by prostate-type epithelium which was confirmed by immunohistochemical tests for prostate specific antigen and prostate acid phosphatase. 9285303 Human
prostate specific antigen localized carcinoma Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate. 9315396 Human
prostate specific antigen ductal carcinomas OBJECTIVES: To confirm the expression of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in ductal carcinomas of the prostate, and to analyse p53, Ki67, oestrogen (ER) and androgen (AR) receptors in these tumours. 9467486 Human
prostate specific antigen breast and ovarian cancer Prostate specific antigen (PSA) in breast and ovarian cancer. 9494598 Human
prostate specific antigen tumour PATIENTS AND METHODS: Sixty-seven patients (median age 63 years, range 48-78) undergoing radical prostatectomy for the treatment of primary prostate cancer were assessed to determine whether age, tumour stage, histological grading, serum levels of prostat 9523661 Human
prostate specific antigen primary prostate cancer PATIENTS AND METHODS: Sixty-seven patients (median age 63 years, range 48-78) undergoing radical prostatectomy for the treatment of primary prostate cancer were assessed to determine whether age, tumour stage, histological grading, serum levels of prostat 9523661 Human
prostate specific antigen intraductal carcinoma OBJECTIVE: To relate the predictive value of serum prostate specific antigen (PSA) levels, histological grade and intraductal carcinoma (IDC-P, a possible marker of poor prognosis) to pathological stage and subsequent clinical outcome, and thus derive an 9523662 Human
prostate specific antigen female breast cancer Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer. 9584052 Human
prostate specific antigen primary carcinoma [The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate] OBJECTIVE: To determine the relationship between the serum level of prostate-specific antigen (PSA) and t 9623236 Human
prostate specific antigen prostatic ductal adenocarcinoma [A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases] In a case histologically proven prostatic ductal adenocarcinoma with endometrioid features associated with rectal invasio 9796260 Human
prostate specific antigen liver metastases [A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases] In a case histologically proven prostatic ductal adenocarcinoma with endometrioid features associated with rectal invasio 9796260 Human
prostate specific antigen primary tumors The peroxidase-anti-peroxidase technique was used to stain for prostate specific acid phosphatase and prostate specific antigen in 12 patients with primary tumors and in 12 patients with metastases in whom the nature of the tumor was in doubt after routin 6339742 Human
prostate specific antigen primary tumors Nine of the primary tumors were positive for both markers and an additional 2 tumors stained for prostate specific antigen only. 6339742 Human
prostate specific antigen lung adenocarcinoma We describe a female patient with lung adenocarcinoma whose tumor extract was highly positive for prostate specific antigen (PSA) immunoreactivity. 9815800 Human
prostate specific antigen recurrent cancer [Potential of ultrasonography and ultrasonography-guided biopsy in the diagnosis of local recurrence following radical prostatectomy] INTRODUTION: We investigated the diagnostic role of combined transrectal US (TRUS) and biopsy to detect recurrent cancer 10051875 Human
prostate specific antigen lung tumor A human non-small cell lung tumor cell line was transfected with a mammalian expression vector containing the gene encoding human prostate specific antigen (PSA) and has been shown to grow progressively following the subcutaneous, intraperitoneal and intr 10648856 Human
prostate specific antigen t1-t2 prostate cancer METHODS AND MATERIALS: Thirty-six consecutive patients with Stage T1/T2 prostate cancer and pretreatment prostate specific antigen (PSA) < 10 ng/ml were treated with EBRT with curative intent at the University of Washington from 1990 through 1996. 10760426 Human
prostate specific antigen organ metastasis Tracking residual disease and predicting outcome is limited to following the level of prostate specific antigen (PSA) production, evaluating for bone or solid organ metastasis, and analyzing their preoperative clinical stage, PSA and Gleason's score. 10854529 Human
prostate specific antigen metastasis The effects of various hormonal treatment regimens on tumor volumes and distant metastasis and the effects of bone stromal cells on prostate specific antigen (PSA) expression by prostate carcinoma cells were evaluated. 10898343 Human
prostate specific antigen tumour infiltrating lymphocytes Strong expression of iNOS was related to high a preoperative prostate specific antigen (PSA) level (P = 0.006) and high pT classification (P < 0.001), but not to nodal status, grade, seminal vesicle or capsular invasion, surgical margin status, perineural 10930922 Human
prostate specific antigen lymph-node metastases Thirty-two patients, including 6 with lymph node metastases, had bone involvement whereas only 5 patients were found to have elevated serum prostate specific antigen (PSA) levels. 11135218 Human
prostate specific antigen breast cyst However, several investigators have demonstrated nonprostatic sources of prostate specific antigen, including amniotic fluid, breast milk, breast cyst fluid, nipple aspirate fluid, and breast tumor cytosol. 11128396 Human
prostate specific antigen undifferentiated carcinoma Tumor markers resulted negative except prostate specific antigen (PSA: 500 mgr/ml) and prostatic acid phosphatase (PAP: 208 U/l); prostate biopsy showed an undifferentiated carcinoma. 11141722 Human
prostate specific antigen bladder cancer Do we have a prostate specific antigen for bladder cancer? 9915423 Human
prostate specific antigen primary malignancy PURPOSE: We examined 4 postulates: 1) radical perineal prostatectomy provides a substantial disease control benefit in men with clinically confined prostate cancer, 2) postoperative prostate specific antigen (PSA) levels are an excellent surrogate end poi 10037390 Human
prostate specific antigen fibrocystic breast disease Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. 10102136 Human
prostate specific antigen breast cyst Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. 10102136 Human
prostate specific antigen breast tumours The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. 10188912 Human
prostate specific antigen prostatic adenocarcinoma KLK3 or prostate specific antigen (PSA) is a serine protease, which is an established tumour marker of prostatic adenocarcinoma. 10188912 Human
prostate specific antigen pancreatic adenocarcinoma Serum prostate specific antigen levels are not elevated in most of the patients with advanced pancreatic adenocarcinoma. 10470664 Human
prostate specific antigen recurrent prostate carcinoma Respondents were asked to describe their follow-up practices for patients treated with curative intent, their motivations regarding postoperative surveillance, their methods of evaluating a postoperative increase in serum prostate specific antigen (PSA) l 10506719 Human
prostate specific antigen metastasis Progression was defined by elevation of serum prostate specific antigen (PSA) > or = 0.4 ng/mL after surgery, development of local recurrence, or distant metastasis documented by biopsy or radiographic examination. 11148561 Human
prostate specific antigen high-grade prostatic intraepithelial neoplasia Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race. 11283929 Human
prostate specific antigen stage a prostate cancer [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer] We compared the usefulness of PSA and PSA 11329957 Human
prostate specific antigen recurrent prostate carcinoma METHODS: Patients with early recurrent prostate carcinoma as indicated by an increasing prostate specific antigen (PSA) level and without any evidence of metastatic disease were treated with oral etoposide 50 mg/m2/day and estramustine 15 mg/kg/day in div 11391599 Human
prostate specific antigen adenoma Focal prostate specific antigen and PSAP positivity were seen in 36% (4 of 11) and 50% (5 of 10) of nephrogenic adenoma cases, respectively. 11395559 Human
prostate specific antigen adenoma In conclusion, nephrogenic adenoma of the prostatic urethra can mimic prostate cancer because of: 1) the presence of tubules, cords, and signet ring-like tubules; 2) prominent nucleoli; 3) muscle involvement; 4) blue-tinged mucinous secretions; 5) focal p 11395559 Human
prostate specific antigen recurrent cancer Prostate specific antigen (PSA) has been proven to be a valuable tool in the diagnosis and staging of early prostate cancer and as a sensitive marker of residual or recurrent cancer after curative therapy. 11564273 Human
prostate specific antigen cyst RESULTS: The round cyst removed with the prostate seemed to arise from the verumontanum and it contained fluid with a high concentration of prostate specific antigen. 11743291 Human
prostate specific antigen localized cancer BACKGROUND: Biochemical failure, defined here as a rise in the serum prostate specific antigen (PSA) concentration to >0.3 ng/mL or the initiation of adjuvant therapy, is thought to be an adverse prognostic factor for men who undergo radical prostatectomy 11790277 Human
prostate specific antigen stage t1c prostate cancer MATERIALS AND METHODS: A total of 81 men (median age 65 years, range 52 to 72) with stage T1c prostate cancer who were thought to have small volume prostate cancer based on needle biopsy findings and prostate specific antigen (PSA) density were followed f 11832703 Human
prostate specific antigen epidermoid carcinoma The biosynthesis of prostate specific antigen (PSA) was studied in human epidermoid carcinoma, (KB) cells and in normal human embryonic lung (WI-38)cells. 11849620 Human
prostate specific antigen testicular cancer The patient was well with no evidence of metastasis from the testicular cancer or prostate cancer and with no elevation of serum alpha-fetoprotein or prostate specific antigen 26 months after the orchiectomy. 11851777 Human
prostate specific antigen recurrent prostate carcinoma The authors examined the utility of indium 111 ((111)In)-capromab pendetide immunoscintigraphy to detect recurrent prostate carcinoma radiographically in men with early biochemical evidence of failure (serum prostate specific antigen [PSA] < or = 4.0 ng/m 11920467 Human
prostate specific antigen metastasis Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation. 11920524 Human
prostate specific antigen metastasis Age, preoperative prostate specific antigen (PSA) level, clinical and pathologic Gleason score, surgical margin, seminal vesicle involvement (SVI), and the number and percentage of involved positive lymph nodes were analyzed to predict PSA progression, me 11920524 Human
prostate specific antigen hyperplastic A series of 20 normal/hyperplastic prostate glands and 60 prostate carcinomas was investigated by immunohistochemistry, using specific antibodies for thymidine phosphorylase (P-GF.44C), tumour-associated macrophages (CD68), endothelium (CD31) and prostate 11986782 Human
prostate specific antigen stage t1c prostate cancer PURPOSE: We developed an algorithm for predicting the likelihood of organ confined disease in patients with clinical stage T1c prostate cancer using biopsy pathology, computer assisted image analysis and serum prostate specific antigen (PSA). 12050500 Human
prostate specific antigen pituitary adenoma Decreasing prostate specific antigen value leading to the diagnosis of a pituitary adenoma. 12050526 Human
prostate specific antigen metastasis Clinical characteristics included the type of treatment for the primary and metastatic prostate carcinoma, age and serum prostate specific antigen (PSA) at the diagnosis of the metastatic prostate carcinoma, radiographic findings of the metastasis (osteob 12209687 Human
prostate specific antigen metastatic prostate carcinoma Clinical characteristics included the type of treatment for the primary and metastatic prostate carcinoma, age and serum prostate specific antigen (PSA) at the diagnosis of the metastatic prostate carcinoma, radiographic findings of the metastasis (osteob 12209687 Human
prostate specific antigen bladder transitional cell carcinoma MATERIALS AND METHODS: Since 1992, 100 patients with a mean age of 64 years (range 48 to 82) underwent cystectomy for bladder transitional cell carcinoma with prostate sparing based on normal digital rectal examination of the prostate, normal prostate spe 12441929 Human
prostate specific antigen brain metastases The prostate gland should be remembered as a possible cause of brain metastases and that a normal serum prostate specific antigen does not exclude this diagnosis. 12463494 Human
prostate specific antigen bone metastasis There were significant differences in TF expression according to the pretreatment prostate specific antigen (PSA) level (p = 0.0193) and bone metastasis (p = 0.0029). 12530031 Human
prostate specific antigen t1c prostate cancer Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer. 12578903 Human
prostate specific antigen stage t1c prostate cancer PURPOSE: Clinicopathological data were reviewed to find a predictor of prostate specific antigen (PSA) failure in Taiwanese patients who had received radical retropubic prostatectomy (RRP) for stage T1c prostate cancer (PC). 12578903 Human
prostate specific antigen prostate tumor IGFBP-2 levels, which are elevated in many malignancies, are markedly increased in prostate cancer, and show a positive correlation with prostate specific antigen (PSA) and prostate tumor aggressiveness. 12672024 Human
prostate specific antigen lymph-node metastases Clinical stage, Gleason score, perineural invasion, number of biopsies containing tumor, and serum prostate specific antigen (PSA) were evaluated as predictors of extracapsular extension, seminal vesicle involvement, lymph node metastases, and surgical ma 12673714 Human
prostate specific antigen mucinous adenocarcinoma of the prostate We report a case of mucinous adenocarcinoma of the prostate which stained positively for prostate specific antigen (PSA) and negatively for carcinoembryonic antigen (CEA) on immunohistochemical study. 12910933 Human
prostate specific antigen differentiated cancers Among patients with available data, 87.5% had a prostate specific antigen (PSA) level of 4 ng/mL or higher, 83.1% had American Joint Committee on Cancer (AJCC) Stage I-II lesions, 80.2% had well or moderately differentiated cancers, and 68.7% of newly dia 12973840 Human
prostate specific antigen villous adenoma Villous adenoma of the urachus: a case with prostate specific antigen immunoreactivity. 14501748 Human
prostate specific antigen recurrent prostate cancer Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. 14501750 Human
prostate specific antigen recurrent prostate cancer MATERIALS AND METHODS: Formalin fixed and frozen specimens of recurrent prostate cancer were obtained by transurethral resection from men with increasing serum level of prostate specific antigen in whom urinary retention developed. 14532783 Human
prostate specific antigen regional cancer The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEAR 14635068 Human
prostate specific antigen maximum tumor We evaluated biopsy Gleason score, maximum tumor length and maximum percentage of tumor in the positive core(s), location and number of positive cores, and total prostate specific antigen before surgery in 295 of these patients. 14634402 Human
prostate specific antigen squamous carcinomas Immunohistochemistry for prostate specific acid phosphatase and prostate specific antigen was positive in a large percentage of the adenocarcinomas (85% and 75%, respectively) and only very focally positive in 12% of the squamous carcinomas. 15105655 Human
prostate specific antigen malignant ascites Diagnosis of malignant ascites in prostate cancer by measurement of prostate specific antigen. 15166746 Human
prostate specific antigen rectal tumor Metastases having a different histologic appearance than the primary rectal tumor or having a pattern suggestive of metastatic PCA were analyzed by immunohistochemistry to detect prostate specific antigen (PSA), prostatic acid phosphatase (PAP), cytokerat 15316314 Human
prostate specific antigen recurrent prostate carcinoma BACKGROUND: The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferator-activated receptor gamma agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change 15468186 Human
prostate specific antigen polycystic-ovary syndrome Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. 15233555 Human
prostate specific antigen metastatic carcinoma The pathological diagnosis of metastatic carcinoma of the prostate was further suggested by an elevation in prostate specific antigen, and was pathologically confirmed following the neurosurgical removal of the tumours. 15345003 Human
prostate specific antigen prostatic ductal adenocarcinoma The aim of the present study is to examine the expression of Bcl-2 and p53 in prostatic ductal adenocarcinoma and to evaluate its origin by analyzing prostate specific antigen, prostate specific acid phosphatase, cytokeratins, epithelial membrane antigen 15379952 Human
prostate specific antigen prostatic ductal adenocarcinoma The results confirmed the expression of prostate specific antigen and prostate specific acid phosphatase in prostatic ductal adenocarcinoma. 15379952 Human
prostate specific antigen transitional cell carcinoma (tcc) Serum prostate specific antigen (PSA) level was high (1,130 ng/ml) suggesting prostate cancer, but transitional cell carcinoma (TCC) was detected by transurethral biopsy. 15471072 Human
prostate specific antigen recurrent prostate cancer Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. 15538231 Human
prostate specific antigen bladder tumor Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model. 15538283 Mouse
prostate specific antigen asap Patient age, digital rectal examination status, prostate specific antigen, free prostate specific antigen, number of cores and biopsy interval were not independent predictors of cancer in men with ASAP. 15592031 Human
prostate specific antigen pheochromocytomas Metastatic lesions from the prostate primary were identified using immunohistochemistry for prostate specific antigen within both primary and metastatic pheochromocytomas in the liver. 15598314 Human
prostate specific antigen intraepithelial neoplasm Predictor variables studied in the nomogram were patient age, family history of prostate cancer, digital rectal examination, serum prostate specific antigen, prostate specific antigen slope, months from initial negative biopsy session, months from previou 15643192 Human
prostate specific antigen male breast cancer Expression of prostate specific antigen in male breast cancer. 15623486 Human
prostate specific antigen male breast cancers Following a case in which metastatic prostatic disease was initially wrongly diagnosed as primary breast cancer, a small series of male breast cancers was examined for expression of prostate specific antigen (PSA) and prostatic acid phosphatase to assess 15623486 Human
prostate specific antigen endobronchial metastasis We confirmed the diagnosis of prostatic cancer and its endobronchial metastasis by immunohistological staining with prostate specific antigen (PSA). 15651277 Human
prostate specific antigen malignant tumors of the prostate Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate. 15678849 Human
prostate specific antigen stage t1c prostate cancer Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. 15711262 Human
prostate specific antigen second cancer Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. 15879786 Human
prostate specific antigen adenoma Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? 15989443 Human
prostate specific antigen recurrent prostate cancer Furthermore, the -174G>C genotype of the IL-6 gene was significantly associated with increased serum prostate specific antigen (p = 0.004) and with recurrent prostate cancer compared with GG homozygotes (p = 0.027). 16006970 Human
prostate specific antigen stage ii prostate cancer We retrospectively reviewed our experience with low dose rate (LDR) and high dose rate (HDR) brachytherapy as a single treatment modality for early prostate cancer with emphasis on chronic toxicity.MATERIALS AND METHODS: From June 1996 to August 2003, 253 16093980 Human
the psa mrna bph The hGK-1 mRNA levels in the BPH specimens studied demonstrated greater variance than the PSA mRNA levels in the same samples. 1691151 Human
the psa protein lung tumor The PSA protein was detected more frequently and at higher levels in lung tumor extracts from men. 9260759 Human
the psa gene bph No significant differences could be found in the PSA gene expression between BPH and CA samples. 1691151 Human
the psa gene breast tumours To determine abnormalities associated with PSA expression in breast tumours, genomic DNA was extracted and all five exons of the PSA gene were polymerase chain reaction (PCR) amplified and sequenced on both strands. 10188912 Human
the psa gene breast tumours The mutations in the core enhancer and promoter region probably contribute to the aberrant expression of the PSA gene in breast tumours, possibly by altering the regulation of the gene by steroid hormones. 10188912 Human
the psa gene ca No significant differences could be found in the PSA gene expression between BPH and CA samples. 1691151 Human
gamma-seminoprotein small-cell carcinoma Immunoperoxidase staining for prostate-specific antigen, prostate-specific acid phosphatase, gamma-seminoprotein, and leu-7 showed positivity only in the adenocarcinoma, whereas neuron-specific enolase was positive only in the small cell carcinoma. 2846913 Human
the psa gene bladder cancer The PSA gene was not detected by RT-PCR of FNAB samples in any of the 20 cases of bladder cancer. 8951475 Human
klk 3 breast tumours The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. 10188912 Human
the psa gene lymph node metastasis Thus RT-PCR for detection of the PSA gene in FNAB samples may be useful as a new diagnostic technique for detection of early lymph node metastasis in prostate cancer and an additional tool for cytological diagnosis of prostate cancer. 8951475 Human
gamma-seminoprotein small cell carcinoma Immunoperoxidase staining for prostate-specific antigen, prostate-specific acid phosphatase, gamma-seminoprotein, and leu-7 showed positivity only in the adenocarcinoma, whereas neuron-specific enolase was positive only in the small cell carcinoma. 2846913 Human
gamma-seminoprotein urogenital cancer [The significance of serum gamma-seminoprotein in prostatic cancer] The level of serum gamma-seminoprotein (gamma-Sm) was determined by enzyme immunoassay using an EIA gamma-Sm test kit in 32 patients with prostatic cancer (before treatment for 12 and aft 2414979 Human
klk3 rcc Since immunoscreening of the RCC library for expressed PSA-like proteins was unsuccessful, polymerase chain reaction (PCR) analysis of the RCC cDNA library was performed using universal KLK primers, directed to the common regions in exon 3 and exon 5 of K 10614994 Human
hk3 salivary gland tumors The aim of this study was to determine whether hK3 and hK5 are expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues. 17177156 Human
hk3 salivary gland tumors Staining was most prominent in keratinizing epithelia in pleomorphic adenomas. hK3 is not expressed in salivary gland tumors. 17177156 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.